gamma-aminobutyric acid has been researched along with Neuralgia, Postherpetic in 118 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Neuralgia, Postherpetic: Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to explore the efficacy and feasibility of cognitive behavioral therapy (CBT) along with pregabalin and compare it with pregabalin monotherapy for the management of neuropathic pain in post-herpetic neuralgia (PHN) patients and to explore the modulation of messenger RNA (mRNA) expression of interleukin (IL)-6 and mammalian target of rapamycin-1 (mTORC1) genes in these patients." | 9.41 | Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study. ( Bajaj, M; Banerjee, A; Banerjee, BD; Bhardwaj, N; Chilkoti, GT; Malik, A; Saxena, AK; Singal, A; Thakur, GK, 2021) |
| "To determine the effect of gastroretentive gabapentin (G-GR) and describe relationships among pain quality, pain impact, and overall-improvement scores in patients with postherpetic neuralgia (PHN)." | 9.20 | Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin. ( Backonja, MM; Freeman, R; Sweeney, M; Wallace, MS, 2015) |
| "To understand how patient demographics and patient-reported disease characteristics relate to successful management of postherpetic neuralgia (PHN), integrated data from phase 3 and phase 4 studies of patients with PHN (n = 546) who received once-daily gastroretentive gabapentin (G-GR, 1800 mg) were analyzed." | 9.20 | Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes. ( Bucior, I; Kantor, D; Panchal, S; Patel, V; Rauck, R, 2015) |
| "This study evaluated the long-term safety and tolerability of a gastroretentive formulation of gabapentin (G-GR) and its effect on weight gain in postherpetic neuralgia (PHN) patients participating in a 14-week, open-label extension to a 10-week double-blind study." | 9.17 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| "The objectives of this study were to identify and determine the validity of early decision criteria following once-daily gastroretentive gabapentin (G-GR) treatment in patients with postherpetic neuralgia (PHN)." | 9.16 | Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia. ( Hsu, PH; Jensen, MP; Vanhove, GF, 2012) |
| "The efficacy of gabapentin in some patients with postherpetic neuralgia (PHN) may be limited by suboptimal drug exposure from unpredictable and saturable absorption." | 9.15 | Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. ( Backonja, MM; Canafax, DM; Cundy, KC, 2011) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 9.14 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "To compare efficacy and safety of 5% lidocaine medicated plaster with pregabalin in patients with post-herpetic neuralgia (PHN) or painful diabetic polyneuropathy (DPN)." | 9.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " Data are reported from the initial 4-week comparative phase, in which adults with PHN or painful DPN received either topical 5% lidocaine medicated plaster applied to the most painful skin area or twice-daily pregabalin capsules titrated to effect according to the Summary of Product Characteristics." | 9.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "One hundred fifty-eight patients with moderate-to-severe postherpetic neuralgia were randomly assigned to 1 of 3 treatment conditions: (1) extended release gabapentin (G-ER) 1800 mg once-daily administered in the evening; (2) G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM); or (3) placebo G-ER." | 9.14 | Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. ( Chiang, YK; Jensen, MP; Wu, J, 2009) |
| "The aim of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN)." | 9.14 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Published analyses have demonstrated that the lidocaine (lignocaine) plaster is a cost-effective treatment for postherpetic neuralgia (PHN) relative to gabapentin or pregabalin." | 9.14 | Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis. ( Liedgens, H; Nuijten, M; Ritchie, M, 2010) |
| "The study did not prove any statistically significant effect of pregabalin in pain relief in patients with acute zoster pain or in the onset of postherpetic neuralgia in comparison with the placebo." | 9.14 | Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence. ( Kamenik, M; Krcevski Skvarc, N, 2010) |
| "The efficacy of pregabalin was demonstrated in a randomized double-blind placebo-controlled 13-week trial in 371 Japanese patients with postherpetic neuralgia (PHN)." | 9.14 | [Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study]. ( Arakawa, A; Ogawa, S; Suzuki, M; Yoshiyama, T, 2010) |
| "Time to onset of pain relief and improvement in allodynia in 269 patients with postherpetic neuralgia was examined in a 4-week randomized trial comparing flexibly dosed pregabalin (150-600 mg/d), fixed-dose pregabalin (300 mg/d), and placebo." | 9.13 | Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. ( Barrett, JA; Phillips, KF; Rowbotham, MC; Stacey, BR; Whalen, E, 2008) |
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 9.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "This trial evaluated the efficacy and safety of pregabalin dosed twice daily (BID) for relief of neuro-pathic pain associated with postherpetic neuralgia (PHN)." | 9.12 | Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. ( Feister, HA; Rigaudy, L; Stoker, M; van Seventer, R; Versavel, M; Young, JP, 2006) |
| "The study aims to systematically evaluate the clinical effect of gabapentin in the treatment of postherpetic neuralgia (PHN)." | 8.98 | A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. ( Dai, ZG; Gao, CX; Li, L; Ma, KT; Si, JQ; Wang, S; Zhang, M, 2018) |
| "Gabapentin, extended-release gabapentin (gabapentin ER), and gabapentin enacarbil (GEn), play an important role in relieving pain associated with postherpetic neuralgia (PHN)." | 8.95 | Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. ( Wang, J; Zhu, Y, 2017) |
| "Electronic databases (PubMed, EBSCO, Ovid MEDLINE, and Web of Science) were systematically searched by terms of "gabapentin [Title/Abstract] AND postherpetic neuralgia [Title/Abstract]" from the year 1966 to present." | 8.95 | Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. ( Wang, J; Zhu, Y, 2017) |
| "In patients with chronic pain due to diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN), pregabalin treatment results in pain relief and improved patient function/quality of life (QoL)." | 8.89 | Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. ( Cheung, R; Emir, B; Vinik, A; Whalen, E, 2013) |
| "Neurontin®, an immediate-release (IR) formulation of gabapentin, was the first drug approved by the United States Food and Drug Administration for the treatment of postherpetic neuralgia (PHN)." | 8.89 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| "Gabapentin immediate-release formulations (G-IR) administered three times a day is an efficacious treatment for postherpetic neuralgia (PHN), but its potential benefits may not be fully realized due to tolerability issues as well as its pharmacokinetic (PK) properties such as its short half-life, and regional and saturable absorption in the proximal small intestine." | 8.88 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| "The purpose of this study was to compare the cost effectiveness of a new 8% capsaicin patch, compared to the current treatments for postherpetic neuralgia (PHN), including tricyclic antidepressants (TCAs), topical lidocaine patches, duloxetine, gabapentin, and pregabalin." | 8.87 | Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. ( Armstrong, EP; Malone, DC; McCarberg, B; Panarites, CJ; Pham, SV, 2011) |
| "MEDLINE and ISI Web of Knowledge databases were searched for randomized double-blind, placebo-controlled clinical trials of pregabalin reporting sleep measures in addition to pain endpoints in patients with painful diabetic peripheral neuropathy and postherpetic neuralgia published from inception through March 2009." | 8.86 | The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. ( Murphy, TK; Roth, T; van Seventer, R, 2010) |
| "Nine trials met the inclusion criteria, providing data for a total of 2399 patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated twice or three times per day with pregabalin (75-600 mg/day) or placebo on a fixed or flexible schedule." | 8.86 | The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. ( Murphy, TK; Roth, T; van Seventer, R, 2010) |
| "In addition to an analgesic benefit, pregabalin may decrease pain-related sleep interference in patients with painful diabetic peripheral neuropathy and postherpetic neuralgia." | 8.86 | The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. ( Murphy, TK; Roth, T; van Seventer, R, 2010) |
| "Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Pregabalin is increasingly being used for the treatment ofneuropathic pain, often as the first-line choice." | 8.84 | [Pregabalin in the treatment of neuropathic pain]. ( Biegstraaten, M; van Schaik, IN, 2007) |
| "To evaluate the safety and effectiveness of once-daily gastroretentive gabapentin (G-GR) for the treatment of postherpetic neuralgia in real-world clinical practice." | 7.81 | Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). ( Dunteman, ED; Kareht, S; Markley, HG; Sweeney, M, 2015) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 7.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster." | 7.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "The combination of gabapentin and valacyclovir administered acutely in patients with herpes zoster reduces the incidence of postherpetic neuralgia." | 7.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "Although both gabapentin and pregabalin are first-line drugs for neuropathic pain including postherpetic neuralgia (PHN), no report has directly compared the magnitude of pain relief and the incidence of side effects of both drugs." | 7.77 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin." | 7.76 | Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. ( Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Puenpatom, RA; Summers, KH; Wei, R, 2010) |
| "This study set out to assess the cost effectiveness of using a 5% lidocaine (lignocaine) medicated plaster for the treatment of postherpetic neuralgia (PHN) compared with gabapentin, pregabalin 300 mg/day or 600 mg/day in German primary care." | 7.74 | Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. ( Dakin, H; Gabriel, A; Hertel, N; Liedgens, H; Mitchell, S; Nautrup, BP; Nuijten, M, 2008) |
| "Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice." | 7.74 | A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. ( Gore, M; Sadosky, A; Stacey, B; Tai, KS, 2007) |
| "The aim of this study was to examine the 12-week cost-effectiveness of 2 treatments of NeP, pregabalin versus gabapentin, in managing diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) in a Canadian setting." | 7.73 | Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. ( Dukes, E; Gordon, A; Rousseau, C; Tarride, JE; Vera-Llonch, M, 2006) |
| "Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons." | 6.84 | Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. ( Bulilete, O; González-Bals, MJ; Leiva, A; Llobera, J; Lorente, P; Roca, A; Rullán, M; Soler, A, 2017) |
| "To characterize risk factors for occurrence of adverse events (AEs) and treatment discontinuations due to AEs for improving safety and tolerability of treatment of postherpetic neuralgia (PHN)." | 6.80 | Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin. ( Bucior, I; Nalamachu, S; Shaparin, N; Slattum, PW, 2015) |
| "Treatment of postherpetic neuralgia (PHN) is more complicated in elderly patients, and multiple daily dosing, complex titration, and high incidences of adverse events can be limiting for many pharmacological treatment options." | 6.78 | Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. ( Gupta, A; Li, S, 2013) |
| " The most common (placebo/G-GR) adverse events (AEs) were dizziness (≥75: 3." | 6.78 | Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. ( Gupta, A; Li, S, 2013) |
| "Treatment options for postherpetic neuralgia (PHN), a complication of herpes zoster, are commonly unsatisfactory and associated with adverse events." | 6.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| " The most frequently reported adverse events were dizziness (G-GR, 11%; placebo, 2%) and somnolence (G-GR, 5%; placebo, 3%)." | 6.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| "PHN pain reduction after G-GR treatment can be observed as early as the second day of dosing and continues for at least 10 weeks." | 6.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| " Safety assessments included the incidence and severity of adverse events (AEs), the occurrence of serious AEs, changes in physical and neurological examination findings, clinical laboratory assessments, and changes in weight." | 6.78 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| " Analyses were performed on safety data from patients who received G-GR for 10 weeks in the randomized controlled study and who then received an additional 14 weeks of G-GR, asymmetrically dosed in the current study." | 6.78 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| "Amitriptyline was administered in a dose of 25 mg once daily and pregabalin in a dose of 75 mg twice daily." | 6.77 | Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. ( Achar, A; Bisai, S; Biswas, A; Chakraborty, PP; Guharay, T, 2012) |
| " This study assessed the efficacy of GEn vs placebo and compared the pharmacokinetics of gabapentin after oral dosing of GEn or gabapentin in patients with PHN." | 6.76 | Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. ( Backonja, MM; Canafax, DM; Cundy, KC, 2011) |
| " Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks." | 6.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Peripheral neuropathic pain presents commonly in clinical practice, and 2 of its most prevalent types are PHN and PDN." | 6.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Lidocaine plaster was also effective in reducing worst pain and showed a fast onset of effect." | 6.75 | Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. ( Baron, R; Binder, A; Rehm, S, 2010) |
| " The commonly reported adverse events were dizziness, somnolence, peripheral edema and weight gain, and most of them were mild to moderate in intensity." | 6.75 | [Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study]. ( Arakawa, A; Ogawa, S; Suzuki, M; Yoshiyama, T, 2010) |
| "Gabapentin ER was well tolerated in this study." | 6.75 | Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. ( Cowles, VE; Irving, G; Wallace, MS, 2010) |
| " Patients administering lidocaine plaster experienced fewer drug-related adverse events (3." | 6.74 | Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "After 4 weeks, 5% lidocaine medicated plaster treatment was associated with similar levels of analgesia in patients with PHN or DPN but substantially fewer frequent adverse events than pregabalin." | 6.74 | Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Postherpetic neuralgia (PHN) and diabetic polyneuropathy (DPN) are two common causes of peripheral neuropathic pain." | 6.74 | Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " Safety evaluation included adverse events (AEs), drug-related AEs (DRAEs), and withdrawal due to AEs." | 6.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 6.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Neuropathic pain is often difficult to treat due to a complex pathophysiology." | 6.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Improvements were comparable between treatments in painful DPN." | 6.74 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Time to onset of pain relief and improvement in allodynia in 269 patients with postherpetic neuralgia was examined in a 4-week randomized trial comparing flexibly dosed pregabalin (150-600 mg/d), fixed-dose pregabalin (300 mg/d), and placebo." | 6.73 | Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. ( Barrett, JA; Phillips, KF; Rowbotham, MC; Stacey, BR; Whalen, E, 2008) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 6.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "This trial evaluated the efficacy and safety of pregabalin dosed twice daily (BID) for relief of neuro-pathic pain associated with postherpetic neuralgia (PHN)." | 6.72 | Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. ( Feister, HA; Rigaudy, L; Stoker, M; van Seventer, R; Versavel, M; Young, JP, 2006) |
| "Pregabalin, dosed BID, reduced neuropathic pain associated with PHN and was well tolerated." | 6.72 | Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. ( Feister, HA; Rigaudy, L; Stoker, M; van Seventer, R; Versavel, M; Young, JP, 2006) |
| "Gabapentin was shown to be equally efficacious but was better tolerated compared to nortriptyline and can be considered a suitable alternative for the treatment of PHN." | 6.72 | Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. ( Chandra, K; Gupta, S; Malhotra, S; Pandhi, P; Shafiq, N, 2006) |
| "0001], but were more likely to experience incidence of adverse events, such as somnolence, dizziness, and peripheral edema." | 6.58 | A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. ( Dai, ZG; Gao, CX; Li, L; Ma, KT; Si, JQ; Wang, S; Zhang, M, 2018) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 6.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Gabapentin was significantly more likely than placebo to lead patients to rate their global impression of change as "much improved" or "very much improved" (RR=1." | 6.50 | Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. ( Li, CL; Li, YW; Liang, R; Liu, Y; Meng, FY; Pan, LH; Qian, W; Zhang, LC; Zhu, M, 2014) |
| "Gabapentin treatment yielded an improvement in pain intensity (risk ratio (RR) 1·88; 95% CI 1·35, 2·29; I(2) = 64·8%; for 50% reduction and RR 1·43; 95% CI 1·12, 1·83; I(2) = 0% for 30% reduction, respectively), PGIC (RR 1·49; 95% CI 1·28, 1·74; I(2) = 0%), and CGIC (RR 1·58; 95% CI 1·29, 1·92; I(2) = 30·9%)." | 6.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| "Treatment with gabapentin 1800 mg/day yielded a significant reduction in PHN up to 14 weeks." | 6.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| "Gabapentin has been used for the management of post-herpetic neuralgia (PHN)." | 6.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| " However, gabapentin increased the somnolence (RR 2·03; 95% CI 1·39, 2·98; I(2) = 2%), dizziness (RR 2·68; 95% CI 1·95, 3·69; I(2) = 15%), peripheral oedema (RR 9·10; 95% CI 3·23, 25·60; I(2) = 2%), total adverse effects (RR 1·28; 95% CI 1·16, 1·42; I(2) = 0%) and withdrawal due to adverse events (RR 1·51; 95% CI 1·06, 2·16; I(2) = 6%), but these adverse effects were often mild to moderate." | 6.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| " Gabapentin 1800 mg appeared safe in treating PHN for up to 24 weeks." | 6.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| " The differences in the dosing frequency and tolerability between G-IR and GR are mainly because of the difference in formulations and thus pharmacokinetic properties." | 6.49 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| " The effective dosing regimen of gabapentin IR (G-IR) for PHN is 1800 mg/day in three divided doses." | 6.49 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| " The gastroretentive once-daily formulation of gabapentin (G-GR) allows for less frequent dosing while maintaining efficacy and may also reduce adverse events (AEs) associated with high plasma concentration of gabapentin occurring during the waking hours." | 6.48 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| " The GR technology used in G-GR resulted in a decreased dosing frequency from three times per day for the IR product to once daily in the treatment of PHN, while maintaining the same efficacy with an apparent reduced incidence of AEs common to G-IR therapy." | 6.48 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| "Gabapentin is a structural analog of gamma aminobutyric acid that binds to the α(2)-δ site of voltage-dependent calcium channels and modulates the influx of calcium, with a resulting reduction in excitatory neurotransmitter release." | 6.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| "Gabapentin has dose-limiting side effects that prevent some patients from achieving therapeutic plasma levels, such as somnolence (27." | 6.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| " Once-daily dosing has been shown to provide comparable drug exposure with an identical daily dose of the immediate-release formulation when administered three times daily." | 6.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| " The new drug combines generic gabapentin with a polymeric delivery system allowing for extended release and is licensed to be given only as a once-daily dosing regimen." | 6.47 | Extended-release gabapentin in post-herpetic neuralgia. ( Farquhar-Smith, P; Thomas, B, 2011) |
| "Although GpER has been approved by the FDA for once-daily use in PHN, there is a relative paucity of data for both its efficacy and the optimum dosing schedule (once or twice a day)." | 6.47 | Extended-release gabapentin in post-herpetic neuralgia. ( Farquhar-Smith, P; Thomas, B, 2011) |
| "Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter gamma-aminobutyric acid (GABA)." | 6.44 | Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. ( Striano, P; Striano, S, 2008) |
| "Desipramine was more effective and less expensive than gabapentin or pregabalin (dominant) under all conditions tested." | 6.44 | A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. ( Holloway, RG; Noyes, K; O'Connor, AB, 2007) |
| "Gabapentin was more effective than pregabalin but at an incremental cost of $216,000/QALY." | 6.44 | A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. ( Holloway, RG; Noyes, K; O'Connor, AB, 2007) |
| "Neuropathic pain is a condition affecting a significant proportion of the world's population." | 6.43 | [Pregabalin. A new treatment for neuropathic pain]. ( López-Trigo, J; Sancho Rieger, J, 2006) |
| " All patients were titrated to 1800 mg G-GR/d over 2 weeks and maintained at that dosage for 6 weeks, for 8 weeks total treatment." | 5.42 | Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). ( Dunteman, ED; Kareht, S; Markley, HG; Sweeney, M, 2015) |
| "This study was designed to explore the efficacy and feasibility of cognitive behavioral therapy (CBT) along with pregabalin and compare it with pregabalin monotherapy for the management of neuropathic pain in post-herpetic neuralgia (PHN) patients and to explore the modulation of messenger RNA (mRNA) expression of interleukin (IL)-6 and mammalian target of rapamycin-1 (mTORC1) genes in these patients." | 5.41 | Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study. ( Bajaj, M; Banerjee, A; Banerjee, BD; Bhardwaj, N; Chilkoti, GT; Malik, A; Saxena, AK; Singal, A; Thakur, GK, 2021) |
| " This study examines dosing patterns, therapy outcomes, healthcare utilization and costs of patients with PHN who initiate treatment with gabapentin or pregabalin." | 5.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| " The mean daily dosage was 826 mg for gabapentin and 187 mg for pregabalin." | 5.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| " Suboptimal dosing and discontinuation may be associated with supplementary use of other analgesics, especially opioids." | 5.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| " The aim of this study was to develop a population pharmacokinetic model and quantify the influence of covariates on the parameters." | 5.37 | Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. ( Bockbrader, HN; Matsui, S; Shoji, S; Suzuki, M; Tomono, Y, 2011) |
| "This pregabalin population pharmacokinetic analysis was conducted on data from 14 clinical trials involving healthy subjects, subjects with impaired renal function and patients with post-herpetic neuralgia or diabetic peripheral neuropathy (n= 616)." | 5.37 | Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. ( Bockbrader, HN; Matsui, S; Shoji, S; Suzuki, M; Tomono, Y, 2011) |
| "In 32 PHN patients being administered gabapentin, without changing the frequency of dosing, the drug was substituted with pregabalin at one-sixth dosage of gabapentin." | 5.37 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| " In the patient group where pregabalin dosage was increased, the VAS pain score decreased significantly compared with that before and after increase the dosage (P < 0." | 5.37 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "It was suggested that the analgesic action of pregabalin in PHN was six times that of gabapentin in terms of effectiveness in dosage conversion." | 5.37 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice." | 5.34 | A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. ( Gore, M; Sadosky, A; Stacey, B; Tai, KS, 2007) |
| "To determine the effect of gastroretentive gabapentin (G-GR) and describe relationships among pain quality, pain impact, and overall-improvement scores in patients with postherpetic neuralgia (PHN)." | 5.20 | Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin. ( Backonja, MM; Freeman, R; Sweeney, M; Wallace, MS, 2015) |
| "To understand how patient demographics and patient-reported disease characteristics relate to successful management of postherpetic neuralgia (PHN), integrated data from phase 3 and phase 4 studies of patients with PHN (n = 546) who received once-daily gastroretentive gabapentin (G-GR, 1800 mg) were analyzed." | 5.20 | Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes. ( Bucior, I; Kantor, D; Panchal, S; Patel, V; Rauck, R, 2015) |
| "This study evaluated the long-term safety and tolerability of a gastroretentive formulation of gabapentin (G-GR) and its effect on weight gain in postherpetic neuralgia (PHN) patients participating in a 14-week, open-label extension to a 10-week double-blind study." | 5.17 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| "The objectives of this study were to identify and determine the validity of early decision criteria following once-daily gastroretentive gabapentin (G-GR) treatment in patients with postherpetic neuralgia (PHN)." | 5.16 | Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia. ( Hsu, PH; Jensen, MP; Vanhove, GF, 2012) |
| "Several classes of medications such as tricyclic antidepressants, anticonvulsants, narcotic analgesics, and α2-δ ligands, such as pregabalin, have been reported to be efficacious in the treatment of painful diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) in whites." | 5.15 | Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. ( Chen, S; Cheng, Y; Cui, L; Ding, X; Fan, D; Guan, Y; Hong, Z; Martin, A; Pan, X; Tan, L; Tang, H; Wang, Y; Zhao, Z; Zhou, D, 2011) |
| "The efficacy of gabapentin in some patients with postherpetic neuralgia (PHN) may be limited by suboptimal drug exposure from unpredictable and saturable absorption." | 5.15 | Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. ( Backonja, MM; Canafax, DM; Cundy, KC, 2011) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 5.14 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "To compare efficacy and safety of 5% lidocaine medicated plaster with pregabalin in patients with post-herpetic neuralgia (PHN) or painful diabetic polyneuropathy (DPN)." | 5.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " Data are reported from the initial 4-week comparative phase, in which adults with PHN or painful DPN received either topical 5% lidocaine medicated plaster applied to the most painful skin area or twice-daily pregabalin capsules titrated to effect according to the Summary of Product Characteristics." | 5.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "One hundred fifty-eight patients with moderate-to-severe postherpetic neuralgia were randomly assigned to 1 of 3 treatment conditions: (1) extended release gabapentin (G-ER) 1800 mg once-daily administered in the evening; (2) G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM); or (3) placebo G-ER." | 5.14 | Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. ( Chiang, YK; Jensen, MP; Wu, J, 2009) |
| "The aim of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN)." | 5.14 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Published analyses have demonstrated that the lidocaine (lignocaine) plaster is a cost-effective treatment for postherpetic neuralgia (PHN) relative to gabapentin or pregabalin." | 5.14 | Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis. ( Liedgens, H; Nuijten, M; Ritchie, M, 2010) |
| "The study did not prove any statistically significant effect of pregabalin in pain relief in patients with acute zoster pain or in the onset of postherpetic neuralgia in comparison with the placebo." | 5.14 | Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence. ( Kamenik, M; Krcevski Skvarc, N, 2010) |
| "The efficacy of pregabalin was demonstrated in a randomized double-blind placebo-controlled 13-week trial in 371 Japanese patients with postherpetic neuralgia (PHN)." | 5.14 | [Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study]. ( Arakawa, A; Ogawa, S; Suzuki, M; Yoshiyama, T, 2010) |
| "Time to onset of pain relief and improvement in allodynia in 269 patients with postherpetic neuralgia was examined in a 4-week randomized trial comparing flexibly dosed pregabalin (150-600 mg/d), fixed-dose pregabalin (300 mg/d), and placebo." | 5.13 | Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. ( Barrett, JA; Phillips, KF; Rowbotham, MC; Stacey, BR; Whalen, E, 2008) |
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 5.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "A total of 338 patients with postherpetic neuralgia or painful diabetic peripheral neuropathy were treated with flexible or fixed regimens of pregabalin at daily doses of up to 600 mg/day (n=141 and 132, respectively) or placebo (n=65)." | 5.12 | [Effectiveness and time to onset of pregabalin in patients with neuropathic pain]. ( Balkenohl, M; Busche, P; Freynhagen, R; Konrad, C, 2006) |
| "This trial evaluated the efficacy and safety of pregabalin dosed twice daily (BID) for relief of neuro-pathic pain associated with postherpetic neuralgia (PHN)." | 5.12 | Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. ( Feister, HA; Rigaudy, L; Stoker, M; van Seventer, R; Versavel, M; Young, JP, 2006) |
| "The study aims to systematically evaluate the clinical effect of gabapentin in the treatment of postherpetic neuralgia (PHN)." | 4.98 | A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. ( Dai, ZG; Gao, CX; Li, L; Ma, KT; Si, JQ; Wang, S; Zhang, M, 2018) |
| " Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| " Effective interventions were described for painful diabetic neuropathy (pregabalin, gabapentin, certain tricyclic antidepressants [TCAs], opioids, antidepressants, and anticonvulsants), postherpetic neuralgia (gabapentin, pregabalin, certain TCAs, antidepressants and anticonvulsants, opioids, sodium valproate, topical capsaicin, and lidocaine), lumbar radicular pain (epidural corticosteroids, repetitive transcranial magnetic stimulation [rTMS], and discectomy), cervical radicular pain (rTMS), carpal tunnel syndrome (carpal tunnel release), cubital tunnel syndrome (simple decompression and ulnar nerve transposition), trigeminal neuralgia (carbamazepine, lamotrigine, and pimozide for refractory cases, rTMS), HIV-related neuropathy (topical capsaicin), and central NeuP (certain TCAs, pregabalin, cannabinoids, and rTMS)." | 4.95 | Interventions for Neuropathic Pain: An Overview of Systematic Reviews. ( Biocic, M; Boric, K; Cavar, M; Dosenovic, S; Jelicic Kadic, A; Markovina, N; Miljanovic, M; Puljak, L; Vucic, K, 2017) |
| "This was a pooled analysis of 19 randomized placebo-controlled trials of pregabalin for peripheral neuropathic pain conditions, including diabetic peripheral neuropathy, postherpetic neuralgia, and post-traumatic/postsurgical pain." | 4.95 | Does Duration of Neuropathic Pain Impact the Effectiveness of Pregabalin? ( Almas, M; Clair, A; Latymer, M; Ortiz, M; Parsons, B; Pérez, C; Varvara, R, 2017) |
| "Gabapentin, extended-release gabapentin (gabapentin ER), and gabapentin enacarbil (GEn), play an important role in relieving pain associated with postherpetic neuralgia (PHN)." | 4.95 | Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. ( Wang, J; Zhu, Y, 2017) |
| "Electronic databases (PubMed, EBSCO, Ovid MEDLINE, and Web of Science) were systematically searched by terms of "gabapentin [Title/Abstract] AND postherpetic neuralgia [Title/Abstract]" from the year 1966 to present." | 4.95 | Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. ( Wang, J; Zhu, Y, 2017) |
| "In patients with chronic pain due to diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN), pregabalin treatment results in pain relief and improved patient function/quality of life (QoL)." | 4.89 | Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. ( Cheung, R; Emir, B; Vinik, A; Whalen, E, 2013) |
| "Gabapentin is approved for the treatment of postherpetic neuralgia (PHN) and epilepsy." | 4.89 | The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. ( Chen, C; Cowles, VE; Sweeney, M, 2013) |
| "Neurontin®, an immediate-release (IR) formulation of gabapentin, was the first drug approved by the United States Food and Drug Administration for the treatment of postherpetic neuralgia (PHN)." | 4.89 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| "Gabapentin immediate-release formulations (G-IR) administered three times a day is an efficacious treatment for postherpetic neuralgia (PHN), but its potential benefits may not be fully realized due to tolerability issues as well as its pharmacokinetic (PK) properties such as its short half-life, and regional and saturable absorption in the proximal small intestine." | 4.88 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| "The purpose of this study was to compare the cost effectiveness of a new 8% capsaicin patch, compared to the current treatments for postherpetic neuralgia (PHN), including tricyclic antidepressants (TCAs), topical lidocaine patches, duloxetine, gabapentin, and pregabalin." | 4.87 | Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. ( Armstrong, EP; Malone, DC; McCarberg, B; Panarites, CJ; Pham, SV, 2011) |
| "MEDLINE and ISI Web of Knowledge databases were searched for randomized double-blind, placebo-controlled clinical trials of pregabalin reporting sleep measures in addition to pain endpoints in patients with painful diabetic peripheral neuropathy and postherpetic neuralgia published from inception through March 2009." | 4.86 | The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. ( Murphy, TK; Roth, T; van Seventer, R, 2010) |
| "Nine trials met the inclusion criteria, providing data for a total of 2399 patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated twice or three times per day with pregabalin (75-600 mg/day) or placebo on a fixed or flexible schedule." | 4.86 | The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. ( Murphy, TK; Roth, T; van Seventer, R, 2010) |
| "In addition to an analgesic benefit, pregabalin may decrease pain-related sleep interference in patients with painful diabetic peripheral neuropathy and postherpetic neuralgia." | 4.86 | The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. ( Murphy, TK; Roth, T; van Seventer, R, 2010) |
| "Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Pregabalin is increasingly being used for the treatment ofneuropathic pain, often as the first-line choice." | 4.84 | [Pregabalin in the treatment of neuropathic pain]. ( Biegstraaten, M; van Schaik, IN, 2007) |
| "This study aimed to explore the changes in gamma-aminobutyric acid (GABA) and glutamate (Glu) levels, and their correlations with clinical indicators in patients with postherpetic neuralgia (PHN)." | 4.12 | Elevated GABA level in the precuneus and its association with pain intensity in patients with postherpetic neuralgia: An initial proton magnetic resonance spectroscopy study. ( Dai, H; Han, S; Li, Y; Wang, L; Wu, X; Yang, Y; Yuan, J, 2022) |
| "Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate or severe neuropathic pain from postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN) is associated with pain reduction of at least 50% in 14% to 17% more patients than placebo." | 3.88 | Gabapentin for Chronic Neuropathic Pain. ( Derry, S; Moore, A; Wiffen, P, 2018) |
| "To evaluate the safety and effectiveness of once-daily gastroretentive gabapentin (G-GR) for the treatment of postherpetic neuralgia in real-world clinical practice." | 3.81 | Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). ( Dunteman, ED; Kareht, S; Markley, HG; Sweeney, M, 2015) |
| " To address this issue, we obtained clinical trial data from the Food and Drug Administration (FDA) through the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership, and harmonized patient level data from 12 clinical trials (4 gabapentin and 8 pregabalin) in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN)." | 3.80 | Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. ( Dworkin, RH; Farrar, JT; Gilron, I; Haynes, K; Katz, NP; Kerns, RD; Rappaport, BA; Rowbotham, MC; Tierney, AM; Troxel, AB; Turk, DC, 2014) |
| "The cost effectiveness of pregabalin as an add-on to the standard treatment of Belgian patients with post-herpetic neuralgia (PHN) had been demonstrated in a previously published Markov model." | 3.79 | Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium. ( Annemans, L; Chevalier, P; Eyckerman, R; Lamotte, M; Van Campenhout, H, 2013) |
| "To compare changes in healthcare resource utilization and costs among members with painful diabetic peripheral neuropathy (pDPN), postherpetic neuralgia (PHN), or fibromyalgia (FM) in a commercial health plan implementing pregabalin step-therapy with members in unrestricted plans." | 3.79 | Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. ( Cappelleri, JC; Joshi, AV; Louder, A; Patel, NC; Suehs, BT; Udall, M, 2013) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 3.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster." | 3.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "The combination of gabapentin and valacyclovir administered acutely in patients with herpes zoster reduces the incidence of postherpetic neuralgia." | 3.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "Although both gabapentin and pregabalin are first-line drugs for neuropathic pain including postherpetic neuralgia (PHN), no report has directly compared the magnitude of pain relief and the incidence of side effects of both drugs." | 3.77 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "To compare changes in medication use and costs over time for management of painful diabetic peripheral neuropathy (pDPN) or postherpetic neuralgia (PHN) among patients in commercial health plans requiring prior authorization (PA) for pregabalin versus patients in plans without pregabalin PA policies." | 3.76 | Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. ( Alvir, J; Cao, Z; Joshi, AV; Margolis, JM; Mullins, CD; Onukwugha, E; Sanchez, RJ, 2010) |
| "To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin." | 3.76 | Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. ( Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Puenpatom, RA; Summers, KH; Wei, R, 2010) |
| "This study set out to assess the cost effectiveness of using a 5% lidocaine (lignocaine) medicated plaster for the treatment of postherpetic neuralgia (PHN) compared with gabapentin, pregabalin 300 mg/day or 600 mg/day in German primary care." | 3.74 | Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. ( Dakin, H; Gabriel, A; Hertel, N; Liedgens, H; Mitchell, S; Nautrup, BP; Nuijten, M, 2008) |
| "Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice." | 3.74 | A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. ( Gore, M; Sadosky, A; Stacey, B; Tai, KS, 2007) |
| "Gabapentin is an antiepileptic drug approved for the treatment of postherpetic neuralgia and as adjunctive therapy for partial seizures." | 3.73 | Gabapentin-induced neurologic toxicities. ( Bookwalter, T; Gitlin, M, 2005) |
| "The aim of this study was to examine the 12-week cost-effectiveness of 2 treatments of NeP, pregabalin versus gabapentin, in managing diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) in a Canadian setting." | 3.73 | Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. ( Dukes, E; Gordon, A; Rousseau, C; Tarride, JE; Vera-Llonch, M, 2006) |
| "Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons." | 2.84 | Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. ( Bulilete, O; González-Bals, MJ; Leiva, A; Llobera, J; Lorente, P; Roca, A; Rullán, M; Soler, A, 2017) |
| "To characterize risk factors for occurrence of adverse events (AEs) and treatment discontinuations due to AEs for improving safety and tolerability of treatment of postherpetic neuralgia (PHN)." | 2.80 | Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin. ( Bucior, I; Nalamachu, S; Shaparin, N; Slattum, PW, 2015) |
| " The most commonly reported adverse events were dizziness and somnolence." | 2.78 | A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). ( Bell, CF; Chen, C; Freeman, R; Graff, O; Harden, RN; Harding, K; Hunter, S; Kavanagh, S; Laurijssens, B; McClung, C; Rainka, M; Schwartzbach, C; Warren, S; Zhang, L, 2013) |
| "Treatment of postherpetic neuralgia (PHN) is more complicated in elderly patients, and multiple daily dosing, complex titration, and high incidences of adverse events can be limiting for many pharmacological treatment options." | 2.78 | Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. ( Gupta, A; Li, S, 2013) |
| " The most common (placebo/G-GR) adverse events (AEs) were dizziness (≥75: 3." | 2.78 | Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. ( Gupta, A; Li, S, 2013) |
| "Treatment options for postherpetic neuralgia (PHN), a complication of herpes zoster, are commonly unsatisfactory and associated with adverse events." | 2.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| " The most frequently reported adverse events were dizziness (G-GR, 11%; placebo, 2%) and somnolence (G-GR, 5%; placebo, 3%)." | 2.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| "PHN pain reduction after G-GR treatment can be observed as early as the second day of dosing and continues for at least 10 weeks." | 2.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| " Safety assessments included the incidence and severity of adverse events (AEs), the occurrence of serious AEs, changes in physical and neurological examination findings, clinical laboratory assessments, and changes in weight." | 2.78 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| " Analyses were performed on safety data from patients who received G-GR for 10 weeks in the randomized controlled study and who then received an additional 14 weeks of G-GR, asymmetrically dosed in the current study." | 2.78 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| "Amitriptyline was administered in a dose of 25 mg once daily and pregabalin in a dose of 75 mg twice daily." | 2.77 | Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. ( Achar, A; Bisai, S; Biswas, A; Chakraborty, PP; Guharay, T, 2012) |
| " This study assessed the efficacy of GEn vs placebo and compared the pharmacokinetics of gabapentin after oral dosing of GEn or gabapentin in patients with PHN." | 2.76 | Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. ( Backonja, MM; Canafax, DM; Cundy, KC, 2011) |
| " Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks." | 2.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Peripheral neuropathic pain presents commonly in clinical practice, and 2 of its most prevalent types are PHN and PDN." | 2.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Lidocaine plaster was also effective in reducing worst pain and showed a fast onset of effect." | 2.75 | Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. ( Baron, R; Binder, A; Rehm, S, 2010) |
| " The commonly reported adverse events were dizziness, somnolence, peripheral edema and weight gain, and most of them were mild to moderate in intensity." | 2.75 | [Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study]. ( Arakawa, A; Ogawa, S; Suzuki, M; Yoshiyama, T, 2010) |
| "Gabapentin ER was well tolerated in this study." | 2.75 | Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. ( Cowles, VE; Irving, G; Wallace, MS, 2010) |
| " Patients administering lidocaine plaster experienced fewer drug-related adverse events (3." | 2.74 | Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "After 4 weeks, 5% lidocaine medicated plaster treatment was associated with similar levels of analgesia in patients with PHN or DPN but substantially fewer frequent adverse events than pregabalin." | 2.74 | Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Postherpetic neuralgia (PHN) and diabetic polyneuropathy (DPN) are two common causes of peripheral neuropathic pain." | 2.74 | Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " Safety evaluation included adverse events (AEs), drug-related AEs (DRAEs), and withdrawal due to AEs." | 2.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 2.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Neuropathic pain is often difficult to treat due to a complex pathophysiology." | 2.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Improvements were comparable between treatments in painful DPN." | 2.74 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Time to onset of pain relief and improvement in allodynia in 269 patients with postherpetic neuralgia was examined in a 4-week randomized trial comparing flexibly dosed pregabalin (150-600 mg/d), fixed-dose pregabalin (300 mg/d), and placebo." | 2.73 | Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. ( Barrett, JA; Phillips, KF; Rowbotham, MC; Stacey, BR; Whalen, E, 2008) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 2.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "They had moderate to severe neuropathic pain despite treatment with gabapentin, a TCA, and a third medication (e." | 2.73 | Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. ( Dworkin, RH; Emir, B; Griesing, T; Murphy, K; Sharma, U; Stacey, BR, 2008) |
| "This trial evaluated the efficacy and safety of pregabalin dosed twice daily (BID) for relief of neuro-pathic pain associated with postherpetic neuralgia (PHN)." | 2.72 | Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. ( Feister, HA; Rigaudy, L; Stoker, M; van Seventer, R; Versavel, M; Young, JP, 2006) |
| "Pregabalin, dosed BID, reduced neuropathic pain associated with PHN and was well tolerated." | 2.72 | Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. ( Feister, HA; Rigaudy, L; Stoker, M; van Seventer, R; Versavel, M; Young, JP, 2006) |
| "Gabapentin was shown to be equally efficacious but was better tolerated compared to nortriptyline and can be considered a suitable alternative for the treatment of PHN." | 2.72 | Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. ( Chandra, K; Gupta, S; Malhotra, S; Pandhi, P; Shafiq, N, 2006) |
| "0001], but were more likely to experience incidence of adverse events, such as somnolence, dizziness, and peripheral edema." | 2.58 | A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. ( Dai, ZG; Gao, CX; Li, L; Ma, KT; Si, JQ; Wang, S; Zhang, M, 2018) |
| "Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage)." | 2.55 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Evidence for other types of neuropathic pain is very limited." | 2.55 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Numerous interventions for neuropathic pain (NeuP) are available, but its treatment remains unsatisfactory." | 2.55 | Interventions for Neuropathic Pain: An Overview of Systematic Reviews. ( Biocic, M; Boric, K; Cavar, M; Dosenovic, S; Jelicic Kadic, A; Markovina, N; Miljanovic, M; Puljak, L; Vucic, K, 2017) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 2.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Gabapentin was significantly more likely than placebo to lead patients to rate their global impression of change as "much improved" or "very much improved" (RR=1." | 2.50 | Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. ( Li, CL; Li, YW; Liang, R; Liu, Y; Meng, FY; Pan, LH; Qian, W; Zhang, LC; Zhu, M, 2014) |
| "Gabapentin treatment yielded an improvement in pain intensity (risk ratio (RR) 1·88; 95% CI 1·35, 2·29; I(2) = 64·8%; for 50% reduction and RR 1·43; 95% CI 1·12, 1·83; I(2) = 0% for 30% reduction, respectively), PGIC (RR 1·49; 95% CI 1·28, 1·74; I(2) = 0%), and CGIC (RR 1·58; 95% CI 1·29, 1·92; I(2) = 30·9%)." | 2.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| "Treatment with gabapentin 1800 mg/day yielded a significant reduction in PHN up to 14 weeks." | 2.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| "Gabapentin has been used for the management of post-herpetic neuralgia (PHN)." | 2.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| " However, gabapentin increased the somnolence (RR 2·03; 95% CI 1·39, 2·98; I(2) = 2%), dizziness (RR 2·68; 95% CI 1·95, 3·69; I(2) = 15%), peripheral oedema (RR 9·10; 95% CI 3·23, 25·60; I(2) = 2%), total adverse effects (RR 1·28; 95% CI 1·16, 1·42; I(2) = 0%) and withdrawal due to adverse events (RR 1·51; 95% CI 1·06, 2·16; I(2) = 6%), but these adverse effects were often mild to moderate." | 2.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| " Gabapentin 1800 mg appeared safe in treating PHN for up to 24 weeks." | 2.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| " It includes the following aspects: 1) the mechanism of gastroretention of gabapentin GR tablets, 2) in vitro dissolution profiles of the GR and IR formulations, 3) site of absorption of gabapentin in the human intestine, 4) studies of the mechanism of gabapentin absorption using intestinal tissue preparations, 5) human PK studies to examine the effects of dose and formulations on PK profiles and the bioavailability of gabapentin at therapeutically relevant doses, and 6) efficacy and safety of gastroretentive gabapentin in patients with PHN." | 2.49 | The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. ( Chen, C; Cowles, VE; Sweeney, M, 2013) |
| " This review focuses on the ADME properties of gabapentin and illustrates how GR delivery enhances its absorption compared with IR formulations and allows once-daily dosing with the evening meal for the treatment of PHN." | 2.49 | The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. ( Chen, C; Cowles, VE; Sweeney, M, 2013) |
| "Gabapentin is approved for the treatment of postherpetic neuralgia (PHN) and epilepsy." | 2.49 | The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. ( Chen, C; Cowles, VE; Sweeney, M, 2013) |
| " The differences in the dosing frequency and tolerability between G-IR and GR are mainly because of the difference in formulations and thus pharmacokinetic properties." | 2.49 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| " The effective dosing regimen of gabapentin IR (G-IR) for PHN is 1800 mg/day in three divided doses." | 2.49 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| " The gastroretentive once-daily formulation of gabapentin (G-GR) allows for less frequent dosing while maintaining efficacy and may also reduce adverse events (AEs) associated with high plasma concentration of gabapentin occurring during the waking hours." | 2.48 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| " The GR technology used in G-GR resulted in a decreased dosing frequency from three times per day for the IR product to once daily in the treatment of PHN, while maintaining the same efficacy with an apparent reduced incidence of AEs common to G-IR therapy." | 2.48 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| "Gabapentin is a structural analog of gamma aminobutyric acid that binds to the α(2)-δ site of voltage-dependent calcium channels and modulates the influx of calcium, with a resulting reduction in excitatory neurotransmitter release." | 2.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| "Gabapentin has dose-limiting side effects that prevent some patients from achieving therapeutic plasma levels, such as somnolence (27." | 2.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| " Once-daily dosing has been shown to provide comparable drug exposure with an identical daily dose of the immediate-release formulation when administered three times daily." | 2.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| " Descriptive safety data from the original trials were reviewed and the most commonly reported adverse events (AEs; dizziness, somnolence, peripheral oedema and weight gain) were identified to be of primary interest." | 2.48 | Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. ( Arakawa, A; Ogawa, S; Satoh, J; Suzuki, M; Yoshiyama, T, 2012) |
| "Once established, postherpetic neuralgia is particularly difficult to treat, and is often resistant to conventional analgesics." | 2.47 | [Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia]. ( Takasaki, I, 2011) |
| " The new drug combines generic gabapentin with a polymeric delivery system allowing for extended release and is licensed to be given only as a once-daily dosing regimen." | 2.47 | Extended-release gabapentin in post-herpetic neuralgia. ( Farquhar-Smith, P; Thomas, B, 2011) |
| "Although GpER has been approved by the FDA for once-daily use in PHN, there is a relative paucity of data for both its efficacy and the optimum dosing schedule (once or twice a day)." | 2.47 | Extended-release gabapentin in post-herpetic neuralgia. ( Farquhar-Smith, P; Thomas, B, 2011) |
| "Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter gamma-aminobutyric acid (GABA)." | 2.44 | Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. ( Striano, P; Striano, S, 2008) |
| "Desipramine was more effective and less expensive than gabapentin or pregabalin (dominant) under all conditions tested." | 2.44 | A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. ( Holloway, RG; Noyes, K; O'Connor, AB, 2007) |
| "Gabapentin was more effective than pregabalin but at an incremental cost of $216,000/QALY." | 2.44 | A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. ( Holloway, RG; Noyes, K; O'Connor, AB, 2007) |
| "Neuropathic pain is a condition affecting a significant proportion of the world's population." | 2.43 | [Pregabalin. A new treatment for neuropathic pain]. ( López-Trigo, J; Sancho Rieger, J, 2006) |
| " All patients were titrated to 1800 mg G-GR/d over 2 weeks and maintained at that dosage for 6 weeks, for 8 weeks total treatment." | 1.42 | Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). ( Dunteman, ED; Kareht, S; Markley, HG; Sweeney, M, 2015) |
| "Amitriptyline was the only antidepressant prescribed commonly as a first-line treatment." | 1.39 | An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. ( Carroll, D; Gabriel, ZL; Hall, GC; McQuay, HJ; Morant, SV, 2013) |
| " This study examines dosing patterns, therapy outcomes, healthcare utilization and costs of patients with PHN who initiate treatment with gabapentin or pregabalin." | 1.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| " The mean daily dosage was 826 mg for gabapentin and 187 mg for pregabalin." | 1.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| " Suboptimal dosing and discontinuation may be associated with supplementary use of other analgesics, especially opioids." | 1.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| " The aim of this study was to develop a population pharmacokinetic model and quantify the influence of covariates on the parameters." | 1.37 | Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. ( Bockbrader, HN; Matsui, S; Shoji, S; Suzuki, M; Tomono, Y, 2011) |
| "This pregabalin population pharmacokinetic analysis was conducted on data from 14 clinical trials involving healthy subjects, subjects with impaired renal function and patients with post-herpetic neuralgia or diabetic peripheral neuropathy (n= 616)." | 1.37 | Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. ( Bockbrader, HN; Matsui, S; Shoji, S; Suzuki, M; Tomono, Y, 2011) |
| "In 32 PHN patients being administered gabapentin, without changing the frequency of dosing, the drug was substituted with pregabalin at one-sixth dosage of gabapentin." | 1.37 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| " In the patient group where pregabalin dosage was increased, the VAS pain score decreased significantly compared with that before and after increase the dosage (P < 0." | 1.37 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "It was suggested that the analgesic action of pregabalin in PHN was six times that of gabapentin in terms of effectiveness in dosage conversion." | 1.37 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "Additionally, gabapentin was given for neuropathic pain uncontrolled by opioids." | 1.37 | [Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer]. ( Ando, A; Nishimura, D; Shibahara, H; Suzuki, S; Uematsu, N, 2011) |
| "Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice." | 1.34 | A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. ( Gore, M; Sadosky, A; Stacey, B; Tai, KS, 2007) |
| "Gabapentin is an antiepileptic drug approved for the treatment of postherpetic neuralgia and as adjunctive therapy for partial seizures." | 1.33 | Gabapentin-induced neurologic toxicities. ( Bookwalter, T; Gitlin, M, 2005) |
| "(1) The first-line treatment for partial epilepsy is carbamazepine monotherapy; gabapentin monotherapy is an alternative, given its lower risk of drug-drug interactions." | 1.33 | Pregabalin: new drug. Very similar to gabapentin. ( , 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (28.81) | 29.6817 |
| 2010's | 81 (68.64) | 24.3611 |
| 2020's | 3 (2.54) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, X | 1 |
| Yuan, J | 1 |
| Yang, Y | 1 |
| Han, S | 1 |
| Dai, H | 1 |
| Wang, L | 1 |
| Li, Y | 1 |
| Zeng, F | 1 |
| Wang, M | 1 |
| Zhang, D | 1 |
| Saxena, AK | 1 |
| Bhardwaj, N | 1 |
| Chilkoti, GT | 1 |
| Malik, A | 1 |
| Thakur, GK | 1 |
| Bajaj, M | 1 |
| Banerjee, A | 1 |
| Banerjee, BD | 1 |
| Singal, A | 1 |
| Wiffen, PJ | 2 |
| Derry, S | 3 |
| Bell, RF | 1 |
| Rice, AS | 3 |
| Tölle, TR | 1 |
| Phillips, T | 1 |
| Moore, RA | 2 |
| Dosenovic, S | 1 |
| Jelicic Kadic, A | 1 |
| Miljanovic, M | 1 |
| Biocic, M | 1 |
| Boric, K | 1 |
| Cavar, M | 1 |
| Markovina, N | 1 |
| Vucic, K | 1 |
| Puljak, L | 1 |
| Moore, A | 1 |
| Wiffen, P | 1 |
| Zhang, M | 1 |
| Gao, CX | 1 |
| Ma, KT | 1 |
| Li, L | 1 |
| Dai, ZG | 1 |
| Wang, S | 1 |
| Si, JQ | 1 |
| Chevalier, P | 1 |
| Lamotte, M | 1 |
| Van Campenhout, H | 1 |
| Eyckerman, R | 1 |
| Annemans, L | 1 |
| Hall, GC | 1 |
| Morant, SV | 1 |
| Carroll, D | 1 |
| Gabriel, ZL | 1 |
| McQuay, HJ | 2 |
| Vinik, A | 2 |
| Emir, B | 5 |
| Cheung, R | 2 |
| Whalen, E | 4 |
| Udall, M | 1 |
| Louder, A | 1 |
| Suehs, BT | 1 |
| Cappelleri, JC | 1 |
| Joshi, AV | 2 |
| Patel, NC | 1 |
| Zhang, L | 3 |
| Rainka, M | 2 |
| Freeman, R | 3 |
| Harden, RN | 3 |
| Bell, CF | 1 |
| Chen, C | 5 |
| Graff, O | 2 |
| Harding, K | 2 |
| Hunter, S | 2 |
| Kavanagh, S | 2 |
| Laurijssens, B | 1 |
| Schwartzbach, C | 2 |
| Warren, S | 2 |
| McClung, C | 2 |
| Athanasakis, K | 1 |
| Petrakis, I | 1 |
| Karampli, E | 1 |
| Vitsou, E | 1 |
| Lyras, L | 1 |
| Kyriopoulos, J | 1 |
| Khadem, T | 1 |
| Stevens, V | 1 |
| Kaye, AD | 2 |
| Kintanar, T | 1 |
| Argoff, CE | 4 |
| Bell, C | 1 |
| Berges, A | 1 |
| Gupta, A | 1 |
| Li, S | 1 |
| Meng, FY | 1 |
| Zhang, LC | 1 |
| Liu, Y | 1 |
| Pan, LH | 1 |
| Zhu, M | 1 |
| Li, CL | 1 |
| Li, YW | 1 |
| Qian, W | 1 |
| Liang, R | 1 |
| Parsons, B | 2 |
| Mandal, S | 1 |
| Biswas, A | 3 |
| Fan, H | 1 |
| Yu, W | 1 |
| Zhang, Q | 1 |
| Cao, H | 1 |
| Li, J | 1 |
| Wang, J | 2 |
| Shao, Y | 1 |
| Hu, X | 1 |
| Farrar, JT | 1 |
| Troxel, AB | 1 |
| Haynes, K | 1 |
| Gilron, I | 2 |
| Kerns, RD | 1 |
| Katz, NP | 1 |
| Rappaport, BA | 1 |
| Rowbotham, MC | 2 |
| Tierney, AM | 1 |
| Turk, DC | 1 |
| Dworkin, RH | 3 |
| Migita, T | 1 |
| Markley, HG | 1 |
| Dunteman, ED | 1 |
| Kareht, S | 1 |
| Sweeney, M | 8 |
| Pickering, G | 1 |
| Johnson, RW | 1 |
| Ryan, NM | 1 |
| Hiom, S | 1 |
| Patel, GK | 1 |
| Newcombe, RG | 1 |
| Khot, S | 1 |
| Martin, C | 1 |
| Shaparin, N | 1 |
| Slattum, PW | 1 |
| Bucior, I | 3 |
| Nalamachu, S | 1 |
| Wallace, MS | 4 |
| Backonja, MM | 2 |
| Kantor, D | 1 |
| Panchal, S | 1 |
| Patel, V | 1 |
| Rauck, R | 2 |
| Pi, ZB | 1 |
| Lin, H | 1 |
| He, GD | 1 |
| Cai, Z | 1 |
| Xu, XZ | 1 |
| Lee, EG | 1 |
| Lee, HJ | 1 |
| Hyun, DJ | 1 |
| Min, K | 1 |
| Kim, DH | 1 |
| Yoon, MS | 1 |
| Calkins, AM | 1 |
| Gudin, J | 1 |
| Gidal, B | 1 |
| Jaros, MJ | 1 |
| Kim, R | 1 |
| Shang, G | 1 |
| Hadley, GR | 1 |
| Gayle, JA | 1 |
| Ripoll, J | 1 |
| Jones, MR | 1 |
| Kaye, RJ | 1 |
| Mehta, N | 1 |
| Bujanover, S | 1 |
| Shah, R | 1 |
| Gulati, A | 1 |
| Pérez, C | 1 |
| Latymer, M | 1 |
| Almas, M | 1 |
| Ortiz, M | 1 |
| Clair, A | 2 |
| Varvara, R | 1 |
| Zhu, Y | 1 |
| Rullán, M | 1 |
| Bulilete, O | 1 |
| Leiva, A | 1 |
| Soler, A | 1 |
| Roca, A | 1 |
| González-Bals, MJ | 1 |
| Lorente, P | 1 |
| Llobera, J | 1 |
| De Smedt, RH | 1 |
| Jaarsma, T | 1 |
| van den Broek, SA | 1 |
| Haaijer-Ruskamp, FM | 1 |
| Striano, P | 1 |
| Striano, S | 1 |
| Stacey, BR | 2 |
| Barrett, JA | 1 |
| Phillips, KF | 1 |
| Liedgens, H | 3 |
| Hertel, N | 1 |
| Gabriel, A | 1 |
| Nuijten, M | 3 |
| Dakin, H | 2 |
| Mitchell, S | 1 |
| Nautrup, BP | 2 |
| Chou, R | 1 |
| Carson, S | 1 |
| Chan, BK | 1 |
| Baron, R | 6 |
| Mayoral, V | 3 |
| Leijon, G | 3 |
| Binder, A | 5 |
| Steigerwald, I | 3 |
| Serpell, M | 3 |
| Cappuzzo, KA | 1 |
| Straube, S | 1 |
| Jensen, MP | 3 |
| Chiang, YK | 1 |
| Wu, J | 1 |
| McKeage, K | 1 |
| Keam, SJ | 1 |
| Zin, CS | 1 |
| Nissen, LM | 1 |
| O'Callaghan, JP | 1 |
| Duffull, SB | 1 |
| Smith, MT | 1 |
| Moore, BJ | 1 |
| Ritchie, M | 1 |
| Stump, P | 1 |
| Rehm, S | 1 |
| Krcevski Skvarc, N | 1 |
| Kamenik, M | 1 |
| Lopez, PR | 1 |
| Rachael, T | 1 |
| Leicht, S | 1 |
| Smalligan, RD | 1 |
| Margolis, JM | 1 |
| Cao, Z | 1 |
| Onukwugha, E | 1 |
| Sanchez, RJ | 1 |
| Alvir, J | 1 |
| Mullins, CD | 1 |
| Barbarisi, M | 1 |
| Pace, MC | 1 |
| Passavanti, MB | 1 |
| Maisto, M | 1 |
| Mazzariello, L | 1 |
| Pota, V | 1 |
| Aurilio, C | 1 |
| Kirson, NY | 1 |
| Ivanova, JI | 1 |
| Birnbaum, HG | 1 |
| Wei, R | 1 |
| Kantor, E | 1 |
| Puenpatom, RA | 1 |
| Ben-Joseph, RH | 1 |
| Summers, KH | 1 |
| Ogawa, S | 2 |
| Suzuki, M | 4 |
| Arakawa, A | 2 |
| Yoshiyama, T | 2 |
| Roth, T | 1 |
| van Seventer, R | 2 |
| Murphy, TK | 3 |
| Irving, G | 2 |
| Cowles, VE | 4 |
| Ong, OL | 1 |
| Churchyard, AC | 1 |
| New, PW | 1 |
| Wolff, RF | 1 |
| Bala, MM | 1 |
| Westwood, M | 1 |
| Kessels, AG | 1 |
| Kleijnen, J | 1 |
| Takasaki, I | 1 |
| Shoji, S | 1 |
| Tomono, Y | 1 |
| Bockbrader, HN | 1 |
| Matsui, S | 1 |
| Armstrong, EP | 1 |
| Malone, DC | 1 |
| McCarberg, B | 1 |
| Panarites, CJ | 1 |
| Pham, SV | 1 |
| Guan, Y | 1 |
| Ding, X | 1 |
| Cheng, Y | 1 |
| Fan, D | 1 |
| Tan, L | 1 |
| Wang, Y | 1 |
| Zhao, Z | 1 |
| Hong, Z | 1 |
| Zhou, D | 1 |
| Pan, X | 1 |
| Chen, S | 1 |
| Martin, A | 1 |
| Tang, H | 1 |
| Cui, L | 1 |
| Lapolla, W | 1 |
| Digiorgio, C | 1 |
| Haitz, K | 1 |
| Magel, G | 1 |
| Mendoza, N | 1 |
| Grady, J | 1 |
| Lu, W | 1 |
| Tyring, S | 1 |
| Canafax, DM | 1 |
| Cundy, KC | 1 |
| Ifuku, M | 1 |
| Iseki, M | 1 |
| Hidaka, I | 1 |
| Morita, Y | 1 |
| Komatus, S | 1 |
| Inada, E | 1 |
| Green, CB | 1 |
| Stratman, EJ | 1 |
| Chen, WH | 1 |
| Yin, HL | 1 |
| Thomas, B | 1 |
| Farquhar-Smith, P | 1 |
| Shibahara, H | 1 |
| Ando, A | 1 |
| Suzuki, S | 1 |
| Uematsu, N | 1 |
| Nishimura, D | 1 |
| Mackey, S | 1 |
| Carroll, I | 1 |
| Dumenci, L | 1 |
| Raymond-Dufresne, E | 1 |
| Fett, N | 1 |
| Cabrera, J | 1 |
| Dills, D | 1 |
| Achar, A | 1 |
| Chakraborty, PP | 1 |
| Bisai, S | 1 |
| Guharay, T | 1 |
| Hsu, PH | 1 |
| Vanhove, GF | 3 |
| Sang, CN | 1 |
| Sathyanarayana, R | 1 |
| Beal, B | 1 |
| Moeller-Bertram, T | 1 |
| Schilling, JM | 1 |
| Satoh, J | 1 |
| Thakur, R | 1 |
| Philip, AG | 1 |
| Davis, TL | 1 |
| Rauck, RL | 1 |
| Irving, GA | 1 |
| Johnson, P | 1 |
| Becker, L | 1 |
| Halpern, R | 1 |
| Bailey, JM | 1 |
| Vandenkerkhof, EG | 1 |
| Wallace, M | 1 |
| Han, CH | 1 |
| Tenser, RB | 1 |
| Freynhagen, R | 1 |
| Busche, P | 1 |
| Konrad, C | 1 |
| Balkenohl, M | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Anderson, HA | 1 |
| Sirinathsinghji, EC | 1 |
| Clapp, RH | 1 |
| Martin, WJ | 1 |
| Kinchington, PR | 2 |
| Krah, DL | 1 |
| Abbadie, C | 1 |
| Fleetwood-Walker, SM | 1 |
| Bookwalter, T | 1 |
| Gitlin, M | 1 |
| Wasner, G | 1 |
| Feister, HA | 1 |
| Young, JP | 1 |
| Stoker, M | 1 |
| Versavel, M | 1 |
| Rigaudy, L | 1 |
| López-Trigo, J | 1 |
| Sancho Rieger, J | 1 |
| Wareham, D | 1 |
| Chandra, K | 1 |
| Shafiq, N | 1 |
| Pandhi, P | 1 |
| Gupta, S | 1 |
| Malhotra, S | 1 |
| Hasnie, FS | 1 |
| Breuer, J | 1 |
| Parker, S | 1 |
| Wallace, V | 1 |
| Blackbeard, J | 1 |
| Lever, I | 1 |
| Dickenson, AH | 1 |
| Pheby, T | 1 |
| Tarride, JE | 1 |
| Gordon, A | 1 |
| Vera-Llonch, M | 1 |
| Dukes, E | 1 |
| Rousseau, C | 1 |
| Lalonde, RL | 1 |
| Kowalski, KG | 1 |
| Hutmacher, MM | 1 |
| Ewy, W | 1 |
| Nichols, DJ | 1 |
| Milligan, PA | 1 |
| Corrigan, BW | 1 |
| Lockwood, PA | 1 |
| Marshall, SA | 1 |
| Benincosa, LJ | 1 |
| Tensfeldt, TG | 1 |
| Parivar, K | 1 |
| Amantea, M | 1 |
| Glue, P | 1 |
| Koide, H | 1 |
| Miller, R | 1 |
| O'Connor, AB | 1 |
| Noyes, K | 1 |
| Holloway, RG | 1 |
| Biegstraaten, M | 1 |
| van Schaik, IN | 1 |
| Bhattachary, R | 1 |
| Gore, M | 1 |
| Sadosky, A | 1 |
| Tai, KS | 1 |
| Stacey, B | 1 |
| Niscola, P | 1 |
| Perrotti, AP | 1 |
| del Poeta, G | 1 |
| Romani, C | 1 |
| Palombi, M | 1 |
| Piccioni, D | 1 |
| Scaramucci, L | 1 |
| Tolu, B | 1 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Abruzzese, E | 1 |
| D'Elia, GM | 1 |
| Brunetti, GA | 1 |
| Maurillo, L | 1 |
| Giovannini, M | 1 |
| Cartoni, C | 1 |
| de Fabritiis, P | 1 |
| Brunnmüller, U | 1 |
| Brasser, M | 1 |
| May, M | 1 |
| Murphy, K | 1 |
| Sharma, U | 1 |
| Griesing, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| Pain Reduction and Changes in Upper Limb Function Produced by Physiotherapy, Ibuprofen Arginine, Gabapentin and the Absence of Treatment, in Carpal Tunnel Syndrome[NCT04025203] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Pain Reduction and Changes in Upper Limb Function Produced by Over the Counter Oral Ibuprofen Versus the Lack of Treatment, in Carpal Tunnel Syndrome.[NCT04328805] | Phase 4 | 45 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Oral Gabapentin Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04285281] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Physical Therapy Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04329247] | 40 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | |||
| Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.[NCT00617461] | Phase 2 | 96 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787] | Phase 2 | 77 participants (Anticipated) | Interventional | 2021-10-25 | Recruiting | ||
| Efficacy of Electroacupuncture Therapy in Patients With Postherpetic Neuralgia: a Multicentre Randomised Controlled Trial[NCT04594226] | 132 participants (Actual) | Interventional | 2020-11-11 | Completed | |||
| Prophylactic Duloxetine Administration During Acute Herpes Zoster Prevents Postherpetic Neuralgia[NCT04313335] | 750 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | |||
| Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy[NCT03571334] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia[NCT00335933] | Phase 3 | 378 participants (Anticipated) | Interventional | 2006-05-31 | Completed | ||
| A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia[NCT00636636] | Phase 3 | 452 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice[NCT01426230] | 201 participants (Actual) | Observational | 2011-09-30 | Completed | |||
| Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain.[NCT00414349] | Phase 3 | 431 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867] | Phase 4 | 0 participants (Actual) | Interventional | 2019-03-22 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| [NCT01250561] | 133 participants (Actual) | Interventional | 2002-02-28 | Completed | |||
| Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin[NCT01821430] | Phase 2 | 4 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to poor recruitment) | ||
| Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia -A Multicenter,Randomized, Double-blind, Placebo-controlled Trial[NCT02868801] | Phase 3 | 280 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline and end of treatment values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (baseline) and the last 7 days on treatment within each period (end of treatment). Participants rated their API over the preceding 24 hours, using an 11-point PI-Numerical Rating Scale (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. Change from baseline was calculated as end of treatment minus baseline. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -1.18 |
| GEn 3600 mg | -1.47 |
Baseline and end of treatment values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (baseline) and the last 7 days on treatment within each period (end of treatment). Participants used a hand-held diary to rate their average pain intensity over the preceding 24 hours, using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. The by period summary is provided as a sensitivity analysis for the primary analysis. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Mean) |
|---|---|
| GEn 1200 mg in First Intervention Period | -1.11 |
| GEn 3600 mg in First Intervention Period | -1.09 |
| GEn 1200 mg in Second Intervention Period | -1.29 |
| GEn 3600 mg in Second Interevention Period | -1.92 |
"Current pain is defined as the participant's assessment of pain intensity right now. Participants recorded their current evening pain intensity in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period." (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -1.10 |
| GEn 3600 mg | -1.39 |
"Current pain is defined as the participant's assessment of pain intensity right now. Participants recorded their current morning pain intensity in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period." (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -1.11 |
| GEn 3600 mg | -1.46 |
Mean daily use of rescue medication (milligrams of acetaminophen) was calculated by determining the average number of tablets taken per day of rescue medication (Commercial Tylenol) during treatment and multiplying that by 500 mg. Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | milligrams (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -68.18 |
| GEn 3600 mg | -71.26 |
Day-time is defined as the time between rising in the morning and going to bed at night. Participants recorded day-time API on a daily basis in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -1.17 |
| GEn 3600 mg | -1.48 |
Day-time worst pain is defined as the participant's assessment of their worst pain intensity between rising in the morning and going to bed at night. Day-time worst pain was recorded in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -1.17 |
| GEn 3600 mg | -1.50 |
Night-time is defined as the time between going to bed in the evening and rising in the morning. Participants recorded night-time API on a daily basis in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -0.92 |
| GEn 3600 mg | -1.21 |
Night-time worst pain is defined as the participant's assessment of their worst pain intensity between going to bed and rising in the morning. Participants recorded night-time worst pain in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and end of treatment scores are as defined for primary endpoint. Change from baseline = the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -0.97 |
| GEn 3600 mg | -1.33 |
Participants assessed sleep interference due to pain on a daily basis using the 11-point NRS (0=pain does not interfere with sleep, 10=pain completely interferes with sleep). Baseline and end of treatment scores are as defined for the primary endpoint. Change from baseline is calculated as the end of treatment score minus the baseline score. An ANCOVA with baseline value, BMI, grouped center as covariates was used. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| GEn 1200 mg | -0.97 |
| GEn 3600 mg | -1.23 |
"The CGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the clinician's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of very much improved or much improved. Data are summarized by dose within each treatment period." (NCT00617461)
Timeframe: End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | participants (Number) |
|---|---|
| GEn 1200 mg in First Intervention Period | 5 |
| GEn 3600 mg in First Intervention Period | 8 |
| GEn 1200 mg in Second Intervention Period | 10 |
| GEn 3600 mg in Second Intervention Period | 10 |
"The CGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the clinician's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of very much improved or much improved. Data are summarized by dose, independent of treatment period." (NCT00617461)
Timeframe: End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | participants (Number) |
|---|---|
| GEn 1200 mg | 15 |
| GEn 3600 mg | 18 |
"The PGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the participant's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of very much improved or much improved Data are summarized by dose, independent of treatment period." (NCT00617461)
Timeframe: End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | participants (Number) |
|---|---|
| GEn 1200 mg | 17 |
| GEn 3600 mg | 28 |
"The PGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the participant's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of very much improved or much improved. Data are summarized by dose within each treatment period." (NCT00617461)
Timeframe: End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | participants (Number) |
|---|---|
| GEn 1200 mg in First Intervention Period | 6 |
| GEn 3600 mg in First Intervention Period | 11 |
| GEn 1200 mg in Second Intervention Period | 11 |
| GEn 3600 mg in Second Intervention Period | 17 |
The BPI assesses the severity and interference of pain; and consists of 6 items assessed on an 11-point NRS (0=no impact to 10=greatest impact). 2 summary scores are calculated: BPI Severity Score (average of first 4 items) and BPI Interference Score (average of 7 responses to item 6); where scores range from 0 to 10 (0=no impact to 10=greatest impact). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of treatment)
| Intervention | points on a scale (Least Squares Mean) | |
|---|---|---|
| Brief Pain Inventory Severity of Pain | Brief Pain Inventory Interference of Pain | |
| GEn 1200 mg | -1.17 | -0.82 |
| GEn 3600 mg | -1.63 | -1.57 |
"Steady-state average (Cave, ss), maximum (Cmax, ss), and minimum (Cmin,ss) plasma concentration of gabapentin in each participant were estimated using the gabapentin plasma concentration data and with the aid of a population pharmacokinetic model. Dispersion is represented by the fifth to ninety-fifth percentile, though labeled as Full Range. A total of 10 blood samples were collected per participant over the Baseline, Period 1, and Period 2 at various timepoints during the dosing interval. Plasma concentration of gabapentin in these samples was measured." (NCT00617461)
Timeframe: A total of 10 blood samples (2 samples at each visit) were collected per participant at Baseline, and the Week 1 and Week 4 visits for each period
| Intervention | micrograms per milliliter (Geometric Mean) | ||
|---|---|---|---|
| Cave,ss | Cmin, ss | Cmax, ss | |
| Gabapentin 1800 mg | 6.8 | 4.3 | 7.4 |
| GEn 1200 mg | 4.1 | 3.0 | 5.1 |
| GEn 3600 mg | 12.4 | 9.2 | 15.2 |
Baseline and end of treatment (EOT) scores are the calculated means of the 24-hour average pain scores for each participant during the last 7 days prior to randomization (Baseline) and the 7 days prior to the last on-treatment completed diary (EOT). Percent reduction from baseline was calculated as the [(EOT score minus baseline score) divided by the baseline score], multiplied by 100. The PI-NRS is an 11-point scale (0=no pain, 10=pain as bad as you can imagine) by which a participant assesses their 24-hour average pain intensity. Data are summarized by dose, independent of treatment period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% or more | 10% or more | 20% or more | 30% or more | 40% or more | 50% or more | 60% or more | 70% or more | 80% or more | 90% or more | 100% | |
| GEn 1200 mg | 68 | 51 | 39 | 28 | 17 | 15 | 6 | 4 | 1 | 1 | 0 |
| GEn 3600 mg | 71 | 49 | 42 | 32 | 26 | 16 | 11 | 5 | 2 | 2 | 2 |
Baseline and end of treatment scores are the calculated means of the 24-hour average pain scores for each participant during the last 7 days prior to randomization (Baseline) and the 7 days prior to the last on-treatment completed diary (end of treatment). Percent reduction from baseline was calculated as the [(end of treatment score minus the baseline score) divided by the baseline score], multiplied by 100. The PI-NRS is an 11-point scale (0=no pain, 10=pain as bad as you can imagine) by which a participant assesses their 24-hour average pain intensity. Data are summarized by period. (NCT00617461)
Timeframe: Baseline and End of Treatment (Weeks 4 and 9, representing the last week of each treatment period)
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% or more | 10% or more | 20% or more | 30% or more | 40% or more | 50% or more | 60% or more | 70% or more | 80% or more | 90% or more | 100% | |
| GEn 1200 mg in First Intervention Period | 38 | 26 | 19 | 13 | 9 | 7 | 1 | 0 | 0 | 0 | 0 |
| GEn 1200 mg in Second Intervention Period | 30 | 25 | 20 | 15 | 8 | 8 | 5 | 4 | 1 | 1 | 0 |
| GEn 3600 mg in First Intervention Period | 34 | 23 | 19 | 13 | 10 | 5 | 3 | 0 | 0 | 0 | 0 |
| GEn 3600 mg in Second Intervention Period | 37 | 26 | 23 | 19 | 16 | 11 | 8 | 5 | 2 | 2 | 2 |
Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary. Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10). (NCT00636636)
Timeframe: 10 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| G-ER | -2.30 |
| Placebo | -1.59 |
"Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as very much improved (score = 1) or much improved (score = 2)." (NCT00636636)
Timeframe: 10 weeks
| Intervention | Participants (Number) |
|---|---|
| G-ER | 97 |
| Placebo | 78 |
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10). (NCT00636636)
Timeframe: 10 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| G-ER | -2.12 |
| Placebo | -1.63 |
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in last observation carried forward (LOCF) average daily pain score from baseline to final week of efficacy treatment period (Week 10). (NCT00636636)
Timeframe: 10 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| G-ER | -2.40 |
| Placebo | -1.85 |
"Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as very much improved (score = 1) or much improved (score = 2)." (NCT00636636)
Timeframe: 10 weeks
| Intervention | Participants (Number) |
|---|---|
| G-ER | 94 |
| Placebo | 77 |
"Change from baseline in pain score on visual analog scale (VAS) (intensity scored from No Pain (0mm) to Worst Possible Pain (100mm)) at Week 8 of treatment; last observation carried forward (LOCF) analysis" (NCT01426230)
Timeframe: 8 weeks (Baseline and Week 8)
| Intervention | scores on a scale (Mean) |
|---|---|
| Open Label - Cohort >70 Yrs Old | -20.4 |
| Open Label - Cohort <=70 Yrs Old | -21.3 |
39 reviews available for gamma-aminobutyric acid and Neuralgia, Postherpetic
| Article | Year |
|---|---|
Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China.
Topics: China; Cost-Benefit Analysis; gamma-Aminobutyric Acid; Humans; Lidocaine; Neuralgia, Postherpetic; P | 2021 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2018 |
Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin.
Topics: Analgesics; Diabetic Neuropathies; gamma-Aminobutyric Acid; Health Surveys; Humans; Neuralgia, Posth | 2013 |
Therapeutic options for the treatment of postherpetic neuralgia: a systematic review.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Approval; Gabapentin; gamm | 2013 |
Evidence-based guidance for the management of postherpetic neuralgia in primary care.
Topics: Amines; Analgesics; Capsaicin; Carbamates; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gab | 2013 |
Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2014 |
Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2014 |
Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Chemistry, Pharmaceutical; Cyclohexanecarboxylic A | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Post-herpetic Neuralgia: a Review.
Topics: Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Evidence-Bas | 2016 |
Does Duration of Neuropathic Pain Impact the Effectiveness of Pregabalin?
Topics: Aged; Analgesics; Diabetic Neuropathies; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; | 2017 |
Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Carbamates; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hu | 2017 |
Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy.
Topics: Amines; Animals; Anticonvulsants; Calcium Channels, L-Type; Clinical Trials as Topic; Cognition; Cyc | 2008 |
Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials.
Topics: Amines; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gabape | 2009 |
Treatment of postherpetic neuralgia: focus on pregabalin.
Topics: Aged; Analgesics; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Humans; Neuralgia, Post | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: Animals; Clinical Trials as Topic; Drug Tolerance; Economics, Pharmaceutical; gamma-Aminobutyric Aci | 2009 |
The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials.
Topics: Analgesics; Diabetic Neuropathies; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Neuralgia, | 2010 |
5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anesthetics, Local; Clinical Trials as Topic; Cyclohe | 2011 |
[Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia].
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors | 2011 |
Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
Topics: Administration, Topical; Amines; Anesthetics, Local; Antidepressive Agents, Tricyclic; Capsaicin; Cl | 2011 |
Review of current guidelines on the care of postherpetic neuralgia.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Capsaicin; Cyclohexanecarb | 2011 |
Extended-release gabapentin in post-herpetic neuralgia.
Topics: Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Gabapent | 2011 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia?
Topics: Acute Pain; Analgesics; Evidence-Based Medicine; gamma-Aminobutyric Acid; Herpes Simplex; Humans; In | 2012 |
Characterizing and understanding body weight patterns in patients treated with pregabalin.
Topics: Adult; Aged; Anticonvulsants; Body Weight; Comprehension; Diabetic Neuropathies; Epilepsies, Partial | 2012 |
Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview.
Topics: Amines; Analgesics; Biological Availability; Chemistry, Pharmaceutical; Cyclohexanecarboxylic Acids; | 2012 |
Gabapentin for once-daily treatment of post-herpetic neuralgia: a review.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Gabapentin; gamm | 2012 |
The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery.
Topics: Amines; Analgesics; Chemistry, Pharmaceutical; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2013 |
Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west.
Topics: Analgesics; Asian People; Diabetic Neuropathies; Dose-Response Relationship, Drug; gamma-Aminobutyri | 2012 |
Chronic pain perspectives: Treating herpes zoster and postherpetic neuralgia: an evidence-based approach.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antipruritics; Capsaicin; | 2012 |
Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Gastr | 2013 |
[Pregabalin. A new treatment for neuropathic pain].
Topics: Analgesics; Animals; Clinical Trials as Topic; Diabetic Neuropathies; gamma-Aminobutyric Acid; Human | 2006 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Amines; Antidepressive Agents, Tricyclic; Antiviral Agents; Arabinofuranos | 2005 |
Model-based drug development.
Topics: Alzheimer Disease; Amines; Analgesics; Animals; Anticholesteremic Agents; Bridged Bicyclo Compounds, | 2007 |
A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Cyclohexanecarbox | 2007 |
[Pregabalin in the treatment of neuropathic pain].
Topics: Analgesics; Cost-Benefit Analysis; Diabetic Neuropathies; Evidence-Based Medicine; gamma-Aminobutyri | 2007 |
36 trials available for gamma-aminobutyric acid and Neuralgia, Postherpetic
| Article | Year |
|---|---|
Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study.
Topics: Analgesics; Cognitive Behavioral Therapy; Feasibility Studies; gamma-Aminobutyric Acid; Humans; Infa | 2021 |
A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthetics; Carbamates; Dose-Response Relationship, Dru | 2013 |
A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Carbamates; Cross-Over Studies; Dose-Response Relationsh | 2013 |
Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delaye | 2013 |
Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double- | 2015 |
Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids | 2015 |
Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2015 |
Randomized and controlled prospective trials of Ultrasound-guided spinal nerve posterior ramus pulsed radiofrequency treatment for lower back post-herpetic neuralgia.
Topics: Administration, Oral; Adult; Aged; Amines; Amitriptyline; Analgesics; Celecoxib; Cyclohexanecarboxyl | 2015 |
Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study.
Topics: Acetaminophen; Acyclovir; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Non-Narcotic; Ant | 2016 |
Impact of Data Imputation Methodology on Pain Assessment over 24 Hours in a Randomized, Placebo-Controlled Study of Gabapentin Enacarbil in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia.
Topics: Adult; Analgesics; Carbamates; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; M | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial.
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Clinical Protocols; Cyclohexanecarboxylic Acids; Do | 2017 |
Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Analysis of Variance; Dose-Response Relationship, Drug; | 2008 |
Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Analgesics; Anesthetics, Local; Capsules; Dia | 2009 |
Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy.
Topics: Aged; Algorithms; Analgesics; Casts, Surgical; Diabetic Neuropathies; Drug Combinations; Female; gam | 2009 |
5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.
Topics: Aged; Algorithms; Analgesics; Casts, Surgical; Diabetic Neuropathies; Female; gamma-Aminobutyric Aci | 2009 |
Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Dose-Response Re | 2009 |
A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
Topics: Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Diabetic Neuropathies; Double-Blind Method; | 2010 |
Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
Topics: Administration, Topical; Analgesics; Anesthetics, Local; Cost-Benefit Analysis; Data Interpretation, | 2010 |
Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study.
Topics: Administration, Topical; Aged; Anesthetics, Combined; Anesthetics, Local; Dosage Forms; Female; gamm | 2010 |
Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence.
Topics: Acute Disease; Adult; Aged; Analgesics; Double-Blind Method; Female; gamma-Aminobutyric Acid; Herpes | 2010 |
Pregabalin and transcutaneous electrical nerve stimulation for postherpetic neuralgia treatment.
Topics: Aged; Aged, 80 and over; Analgesics; Chi-Square Distribution; Combined Modality Therapy; Female; gam | 2010 |
[Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study].
Topics: Adolescent; Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neu | 2010 |
Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study.
Topics: Administration, Oral; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparat | 2010 |
Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
Topics: Adolescent; Adult; Aged; Analgesics; China; Diabetic Neuropathies; Dose-Response Relationship, Drug; | 2011 |
Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.
Topics: Adult; Aged; Amines; Analgesics; Carbamates; Cyclohexanecarboxylic Acids; Double-Blind Method; Femal | 2011 |
Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia.
Topics: Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Female; gamma-Aminobutyric Acid; Humans; Male; | 2012 |
Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2012 |
Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep | 2013 |
Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Amines; Analgesics; Causality; Comorbidity; Cyclohexanecarboxylic Acids; Disorders of Excessive Somn | 2013 |
Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep | 2013 |
[Effectiveness and time to onset of pregabalin in patients with neuropathic pain].
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Female; gamma-Ami | 2006 |
Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions | 2006 |
Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
Topics: Aged; Amines; Analgesics; Capsules; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; D | 2006 |
Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study.
Topics: Adolescent; Adult; Aged; Anxiety; Diabetic Neuropathies; Dizziness; Dose-Response Relationship, Drug | 2008 |
Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial.
Topics: Analgesics; Diabetic Neuropathies; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Neuralgia; | 2008 |
43 other studies available for gamma-aminobutyric acid and Neuralgia, Postherpetic
| Article | Year |
|---|---|
Elevated GABA level in the precuneus and its association with pain intensity in patients with postherpetic neuralgia: An initial proton magnetic resonance spectroscopy study.
Topics: Choline; Creatine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neuralgia, Postherpetic; Pain Mea | 2022 |
Gabapentin for Chronic Neuropathic Pain.
Topics: Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gabape | 2018 |
Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Topics: Aged; Analgesics; Belgium; Computer Simulation; Cost-Benefit Analysis; Dose-Response Relationship, D | 2013 |
An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population.
Topics: Acetaminophen; Adolescent; Adult; Aged; Amines; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, | 2013 |
Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.
Topics: Adolescent; Adult; Aged; Analgesics; Cost Control; Databases, Factual; Diabetic Neuropathies; Female | 2013 |
Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Topics: Amines; Analgesics; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Femal | 2013 |
Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Diabetic Neuropathies; Female; gamma-Aminobutyric Acid; | 2014 |
Shift-invariant target in allocation problems.
Topics: Computer Simulation; gamma-Aminobutyric Acid; Humans; Models, Statistical; Neuralgia, Postherpetic; | 2014 |
Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathi | 2014 |
Can early administration of pregabalin reduce the incidence of postherpetic neuralgia?
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Female; gamma-Aminobutyric Acid; Herpes Zoster; Humans; | 2014 |
Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN).
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids | 2015 |
Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gaba | 2015 |
[Shingles symptoms are gone but not the pain].
Topics: Administration, Cutaneous; Administration, Oral; Aged; Amines; Amitriptyline; Analgesics; Anti-Infla | 2015 |
Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report.
Topics: Aged; Anticonvulsants; Bumetanide; Chronic Disease; gamma-Aminobutyric Acid; Heart Failure; Herpes Z | 2008 |
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Topics: Administration, Cutaneous; Amines; Analgesics; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; D | 2008 |
[Pregabalin--profile of efficacy and tolerability in neuropathic pain].
Topics: Analgesics; Diabetic Neuropathies; gamma-Aminobutyric Acid; Humans; Neuralgia; Neuralgia, Postherpet | 2009 |
Gabapentin-induced delusions of parasitosis.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delusions; Female; Gabapentin; gamma-Aminobut | 2010 |
Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.
Topics: Analgesics; Diabetic Neuropathies; Drug Costs; Drug Utilization; Follow-Up Studies; gamma-Aminobutyr | 2010 |
Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Topics: Amines; Analgesics; Costs and Cost Analysis; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma- | 2010 |
The importance of early diagnosis of herpes zoster myelitis.
Topics: Acyclovir; Aged; Amines; Analgesics; Anti-Inflammatory Agents; Antiviral Agents; Cyclohexanecarboxyl | 2010 |
Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy.
Topics: Adult; Aged; Analgesics; Clinical Trials as Topic; Diabetic Neuropathies; gamma-Aminobutyric Acid; H | 2011 |
Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study.
Topics: Acute Disease; Acyclovir; Aged; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; D | 2011 |
Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma- | 2011 |
Prevent rather than treat postherpetic neuralgia by prescribing gabapentin earlier in patients with herpes zoster: comment on "incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes z
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; ga | 2011 |
Successful amelioration of tinnitus in a stroke patient by low-dose gabapentin.
Topics: Amines; Audiometry, Pure-Tone; Basal Ganglia Hemorrhage; Cerebral Angiography; Cyclohexanecarboxylic | 2012 |
[Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer].
Topics: Aged; Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Fentanyl; gamma-Aminobutyric Acid; Humans; | 2011 |
Once-daily gabapentin (Gralise) for postherpetic neuralgia.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Gabapentin; gamma-Ami | 2011 |
Sensory pain qualities in neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Cohort Studies; Diabetic Neuropathies; Dose-Response Rel | 2012 |
Gabapentin not shown to prevent postherpetic neuralgia.
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Female; gamma-Aminobut | 2012 |
Postherpetic neuralgia: treatment strategies for pain control.
Topics: Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Ac | 2012 |
Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin.
Topics: Adolescent; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delivery of Health Care; D | 2013 |
Chronobiological characteristics of neuropathic pain: clinical predictors of diurnal pain rhythmicity.
Topics: Amines; Analgesics; Analysis of Variance; Circadian Rhythm; Cyclohexanecarboxylic Acids; Diabetic Ne | 2013 |
Herpes zoster and the prevention of postherpetic neuralgia: beyond antiviral therapy.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antiviral Agents; Calcium Channels; Clinical Trials as | 2005 |
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2005 |
Gabapentin-induced neurologic toxicities.
Topics: Acute Kidney Injury; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2005 |
Pregabalin: new drug. Very similar to gabapentin.
Topics: Amines; Amitriptyline; Anticonvulsants; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclohexane | 2005 |
Prevention and treatment of postherpetic neuralgia.
Topics: Adult; Amines; Anesthetics, Local; Antiviral Agents; Calcium Channel Blockers; Child, Preschool; Cyc | 2006 |
Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.
Topics: Amines; Analgesics; Animals; Anti-Anxiety Agents; Anxiety Disorders; Cells, Cultured; Cyclohexanecar | 2007 |
Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Topics: Amines; Analgesics; Canada; Clinical Trials as Topic; Costs and Cost Analysis; Cross-Sectional Studi | 2006 |
Optimal response-adaptive designs for continuous responses in phase III trials.
Topics: Analgesics; Clinical Trials, Phase III as Topic; Computer Simulation; gamma-Aminobutyric Acid; Human | 2007 |
Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
Topics: Administration, Cutaneous; Aged; Amines; Analgesics; Anesthetics, Local; Cost-Benefit Analysis; Cycl | 2007 |
A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; | 2007 |
Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures.
Topics: Acute Disease; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic | 2007 |